Abiopharma

🔍 Bressman Andrew (Executive)

Company: ATLANTIC INTERNATIONAL CORP. (ATLN)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Acquired 500,000 shares of Common Stock, $.00001 par value at $1.33 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,003,971.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 500,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-05 | Code: A | Expires: 2031-01-04 | Exercise: 2026-01-05 | equity_swap_involved: 0 | shares_owned_after: 500,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents shares of common stock vested upon exercise of the restricted stock units (the "RSUs") awarded under the Issuer's 2025 Omnibus Equity Incentive Plan pursuant to Rule 16b-3 under the Securities Exchange Act of 1934. This does not represent a discretionary transaction by a reporting person.
• F2: These shares were valued at $1.33 per share, the closing market price on December 31, 2025.
• F3: These RSUs were granted under the terms of the Consulting Agreement. by and between the Issuer and SAB Management LLC, of which the Reporting Person is Manager. They vested in their entirety on the date of grant.